RESUMEN
HER-2/neu is the human epidermal growth factor receptor 2, which is associated with the progression of prostate cancer (PCa). HER-2/neu-specific T cell immunity has been shown to predict immunologic and clinical responses in PCa patients treated with HER-2/neu peptide vaccines. However, its prognostic role in PCa patients receiving conventional treatment is unknown, and this was addressed in this study. The densities of CD8+ T cells specific for the HER-2/neu(780-788) peptide in the peripheral blood of PCa patients under standard treatments were correlated with TGF-ß/IL-8 levels and clinical outcomes. We demonstrated that PCa patients with high frequencies of HER-2/neu(780-788)-specific CD8+ T lymphocytes had better progression-free survival (PFS) as compared with PCa patients with low frequencies. Increased frequencies of HER-2/neu(780-788)-specific CD8+ T lymphocytes were also associated with lower levels of TGF-ß and IL-8. Our data provide the first evidence of the predictive role of HER-2/neu-specific T cell immunity in PCa.
Asunto(s)
Vacunas contra el Cáncer , Neoplasias de la Próstata , Humanos , Masculino , Epítopos , Interleucina-8 , Linfocitos T CD8-positivos , Receptor ErbB-2/metabolismoRESUMEN
The prognostic value of human leukocyte antigen (HLA) class I molecules in prostate cancer (PCa) remains unclear. Herein, we investigated the prognostic relevance of the most frequently expressed HLA-A alleles in Greece (A*02:01 and HLA-A*24:02) in de novo metastatic hormone-sensitive PCa (mPCa), which is a rare and aggressive disease characterized by a rapid progression to castration-resistance (CR) and poor overall survival (OS), contributing to almost 50% of PCa-related deaths. We identified 56 patients who had either progressed to CR (these patients were retrospectively analyzed for the time to the progression of CR and prospectively for OS) or had at least three months' follow-up postdiagnosis without CR progression and, thus, were prospectively analyzed for both CR and OS. Patients expressing HLA-A*02:01 showed poor clinical outcomes vs. HLA-A*02:01-negative patients. HLA-A*24:02-positive patients progressed slower to CR and had increased OS. Homozygous HLA-A*02:01 patients progressed severely to CR, with very short OS. Multivariate analyses ascribed to both HLA alleles significant prognostic values for the time to progression (TTP) to CR and OS. The presence of HLA-A*02:01 and HLA-A*24:02 alleles in de novo mPCa patients are significantly and independently associated with unfavorable or favorable clinical outcomes, respectively, suggesting their possible prognostic relevance for treatment decision-making in the context of precision medicine.
RESUMEN
We present 2 cases of large bladder stones formed on a tension-free vaginal tape (TVT) which was inadvertently passed through the bladder during the continence procedure. The stones together with the intravesical portion of the slings were removed using a suprapubic approach. High clinical suspicion of bladder complications is necessary when evaluating patients with urinary symptoms after a TVT operation.
Asunto(s)
Procedimientos Quirúrgicos Ginecológicos/efectos adversos , Cabestrillo Suburetral/efectos adversos , Cálculos de la Vejiga Urinaria/etiología , Vejiga Urinaria/lesiones , Anciano , Femenino , Procedimientos Quirúrgicos Ginecológicos/instrumentación , Humanos , Persona de Mediana Edad , Cálculos de la Vejiga Urinaria/cirugíaRESUMEN
Double-J ureteral stent insertion is a common urological procedure performed for the relief of ureteral obstruction or as a part of other endourological procedures. Several complications have been reported in the past. A case of a 62-year-old woman who was stented due to hydronephrosis of her solitary functioning left kidney and had renal perforation and retroperitoneal hematoma formation is presented. She was managed conservatively with blood transfusion and double-J stent repositioning in the collecting system the fifth postoperative day. Follow-up noncontrast computed tomography (CT) of the abdomen was performed the first and third months after stent placement which showed stabilization of the hematoma.